FDA approves Ascendis Pharma's Yorvipath hormone disorder therapy for US adult hypoparathyroidism patients.

Ascendis Pharma's Yorvipath, a hormone disorder therapy, has been approved by the FDA for adult patients with hypoparathyroidism, a rare endocrine disease affecting approximately 70,000 to 90,000 people in the US. Yorvipath will be the only approved treatment in the US after Takeda discontinues its injection, Natpara, at the end of 2022. Ascendis anticipates initial supply to be available in Q1 2025.

August 12, 2024
9 Articles